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LETTERS TO
THE EDITOR
Facial diplegia with paraesthesias: facial
nerve enhancement in three dimens-
ional MRI
Facial diplegia (bilateral facial paralysis) is a
rare clinical finding that can be the presenting
symptom in a wide range of diseases.1 It
occurs in about 50% of patients with
Guillain-Barré syndrome (GBS). Guillain-
Barré syndrome causes regional and func-
tional variants with unusual features. Ropper
described four patients with facial diplegia
and distal limb paraesthesias, and he defined
them as having a rare variant form of GBS
because of shared clinical, electrophysiologi-
cal, and CSF features.2 The aetiology and
nosological position of facial diplegia pre-
senting in this variant form is still controver-
sial. We experienced a patient who had bilat-
eral facial paralysis, distal limb paraesthesias,
and diminished reflexes whose contrast en-
hanced three dimensional MRI (3-D MRI)
showed enhancing lesions in the bilateral
facial nerves.
A 27 year old woman had nasal discharge
and coughing. One week later she noticed
paraesthesias in her fingers and toes. Nine
days after the onset of her neurological symp-
tom, she developed bilateral facial weakness.
On admission (day 12) she showed moderate,
bilateral facial paralysis that caused her
diYculty in moving her forehead, in approxi-
mating her eyelids, and in lifting the corners of
her mouth. Tearing and taste were preserved.
The other cranial nerves were normal. A
motor examination showed normal strength
in her limbs. Superficial and deep senses were
normal even though she had distal limb
paraesthesias. Deep tendon reflexes were
absent in all her limbs and her plantar
responses were flexor type. Cerebellar ataxia
and autonomic nervous dysfunction were
excluded. Chest radiography was normal.
Laboratory studies of the identifiable causes
of facial diplegia (sarcoidosis, Lyme disease,
syphilis, infectious mononucleosis, herpes
simplex virus, diabetes mellitus, and connec-
tive tissue disease) were all negative. On day
12, the CSF examination detected mild
increases in protein concentration (57 mg/dl)
without pleocytosis. The blink reflex was elic-
ited and both the R1 and R2 components
were reduced, but their latencies were not
prolonged on day 15. Motor and sensory
nerve conduction velocities, and median and
tibial nerve fresponses were all normal on day
18. Auditory brainstem responses were nor-
mal. On Day 19, when her facial diplegia was
moderate, conventional brain MRI detected
no abnormality. A contrast enhanced 3-D
MRI, which was obtained by spoiled gradient
recalled acquisition in the steady state se-
quence using a 1.5 tesla system after injection
of gadolinium-diethylenetriamine penta-
acetic acid (Gd-DTPA), was performed. The
intracanalicular segments of the bilateral
facial nerves were remarkably enhanced by
Gd-DTPA (figure). On Day 45, when her
symptoms were no longer present, there were
no abnormal enhancements of her facial
nerves.
After showing symptoms of upper respira-
tory infection, the patient experienced the
acute onset of facial diplegia, distal limb par-
aesthesias, and areflexia but no other neuro-
logical deficits. The CSF examination
showed albuminocytological dissociation,
and clinical and laboratory examinations
excluded the possibility of viral or bacterial
infection, Lyme disease, tumour, sarcoidosis,
cerebrovascular disease, diabetes mellitus,
bilateral Bell’s palsy, and congenital and
familial disorders. The patient’s illness fol-
lowed a monophasic course. We therefore
diagnosed this case as having “facial diplegia
with paraesthesias”, which should be in-
cluded for the diVerential diagnosis whenever
sudden bilateral facial paresis occurs. Routine
brain MRI showed no abnormalities, whereas
contrast enhanced 3-D MRI showed Gd
enhancement of the bilateral facial nerves.
The MRI findings indicate the involvement
of the peripheral facial nerves in our patient.
Fulbright et al3 reported an additional case of
GBS with multiple cranial nerve enhance-
ments seen on Gd enhanced MRI. The
mechanism of abnormal enhancement of the
cranial nerves in the patients with GBS is not
entirely understood; however, it is widely
regarded as disruption of the blood nerve
barrier by the inflammatory infiltrate. Ram-
sey et al4 evaluated the MRI findings obtained
with Gd contrast enhancement in five pa-
tients who had acute bilateral facial paralysis:
GBS (n=1), herpes simplex polyneuritis
(n=1), meningeal lymphoma (n=1), and
bilateral Bell’s palsy (n=2). Gd enhanced
MRI has been shown to be the procedure of
choice for demonstrating inflammatory le-
sions of the facial nerves. Nagaoka et al5
showed oculomotor nerve enhancement on
3-D MRI in Fisher’s syndrome, the best
known variant of GBS. Ours is the first report
of facial nerve enhancement in “facial
diplegia with paraesthesias”. These findings
suggest that 3-D MRI with Gd-DTPA can be
used to identify inflammatory conditions that
produce peripheral lesion of the cranial
nerves in GBS variants.
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Restless legs syndrome associated with
spinal cord lesions
Restless legs syndrome may be either a
primary or a secondary disorder. The pri-
mary form of the syndrome is often familial
whereas the secondary form is mainly associ-
ated with uraemia, iron deficiency, or preg-
nancy. Almost all patients with restless legs
syndrome show periodic leg movements dur-
ing sleep.1 The pathogenesis of both restless
legs syndrome and periodic leg movements is
still speculative. Yokota et al have reported an
association of periodic leg movements with
spinal cord lesions.2 However, none of these
patients had the typical clinical features of
restless legs syndrome. Restless legs syn-
drome associated with myelopathy is docu-
mented in one patient with a Borrelia
induced myelitis.3 We report three patients
who developed a restless legs syndrome in
close temporal association with spinal cord
lesions.
Case 1 was a 35 year old woman who pre-
sented with a 3 week history of painless rest-
lessness of her left lower leg that occurred
only at rest, particularly in the evening and at
night. The restlessness was partially relieved
by walking. With the onset of these symp-
toms, the patient had noticed a numbness of
her left hemibody below the breast. Nine
months previously, a numbness of the right
leg had subsided spontaneously within 1
week. On examination, the patient had
decreased senses for touch, pain, and tem-
perature over the left hemibody below the T6
dermatome. Examination of CSF disclosed a
normal cell count, normal protein content,
increased CNS synthesis of IgG, and positive
oligoclonal bands. In MRI studies of the spi-
nal cord, no abnormality was detected. Brain
MRI was not performed. Transcranial mag-
netic stimulation showed a slightly prolonged
central conduction time of motor evoked
potentials recorded over the left abductor
hallucis muscle. Otherwise, multimodality
evoked potentials were normal. A myelitis
due to multiple sclerosis accompanied by a
symptomatic unilateral restless legs syn-
drome was diagnosed. The patient was
treated with 500 mg prednisolone intrave-
nously over 5 days without any clinical eVect.
However, a single dose of 100 mg levodopa
plus benserazide led to a dramatic improve-
ment of the restless legs syndrome. The levo-
dopa treatment was continued and resulted
in complete relief.
Case 2 was a 49 year old man who had a
traumatic atlantoaxial dislocation that neces-
sitated operative stabilisation of the cervical
spine. Preoperative MRI studies had shown a
compression of the medulla and the cervical
cord. When we saw the patient 3 years later,
he complained of a sensation of cold, pain,
and restlessness in both lower legs that was
present only at rest, particularly in the
(A) Before and (B) after contrast enhanced
transverse reformatted three dimensional MRI.
The lateral intracanalicular segments of both
facial nerves are enhanced (arrows) in B.
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evening, and was relieved by walking around
and rubbing the legs with cold water. The
onset of these symptoms was only a few weeks
after the accident. Clinical examination
disclosed a mild dysarthrophonia and
atrophic pareses of the left sternomastoid and
the left trapezius muscle. Tendon reflexes
were hyperactive and plantar responses were
extensor bilaterally. The patient’s gait was
spastic, but he was able to walk unassisted. In
both legs, pain and temperature sensation
were markedly reduced. The diagnosis of a
restless legs syndrome secondary to a trau-
matic lesion of the medulla and the cervical
cord was made. Treatment with 100 mg levo-
dopa plus benserazide and 100 mg tramadol
resulted in a satisfactory relief of the restless
legs syndrome.
Case 3 was a 65 year old man who
developed slowly progressive spastic tetra-
paresis and ascending sensory disturbances in
both legs. An MRI study showed a cervical
spondylotic myelopathy at the level C3-C6
and the patient underwent spinal cord
decompression. Five years later, he was
referred to our hospital because of an intense
sensation of restlessness of both legs located
in the feet and calves. The restlessness
occurred when sitting and lying for more than
20 minutes. It was pronounced at night and
improved when he was walking around.
These symptoms had started simultaneously
with the motor and sensory disturbances due
to the cervical spondylotic myelopathy and
did not improve postoperatively. On exam-
ination, the patient was mildly impaired in
carrying out fine motor tasks and his gait was
moderately spastic. He had reduced touch
and vibration senses in both upper limbs. A
restless legs syndrome due to a cervical
spondylotic myelopathy was diagnosed.
Treatment with pergolide resulted in an
excellent control of the restless legs syn-
drome.
Our patients meet the criteria for the diag-
nosis of restless legs syndrome.4 Over a follow
up period of at least 6 months, restless legs
syndrome symptoms were suYciently re-
lieved by dopaminergic treatment. The as-
sociation of myelopathy and restless legs syn-
drome may be merely coincidental. However,
the close temporal relation between the onset
of myelopathy and restless legs syndrome
strongly suggests that restless legs syndrome
was secondary to the spinal cord lesions.
The pathogenesis of restless legs syndrome
and periodic leg movements is still specula-
tive. In patients with myelopathy and periodic
leg movements, it is hypothesised that a spinal
cord lesion may permit the expression of a
spinal periodic leg movements generator by
interrupting descending inhibitory spinal
pathways.2 Our finding of restless legs syn-
drome in three patients with myelopathy pro-
vides evidence that disinhibition of spinal
pathways may also be involved in its patho-
genesis.
In patient 1, restless legs syndrome was
strictly confined to the left leg. Preceding
transitory sensory disturbances of the right
leg and CSF findings support the diagnosis of
multiple sclerosis in this patient. Clinical
findings suggest a spinal lesion at the thoracic
level. Involvement above the spinal level can-
not be excluded. However, clinically and
neurophysiologically no supraspinal lesion
was detected. Yokota et al described three
cases of periodic leg movements associated
with spinal lesions due to multiple sclerosis.2
Ferini-Strambi et al performed polysomno-
graphic studies in 25 patients with multiple
sclerosis and in an age and sex matched con-
trol group.5 The prevalence of periodic leg
movements was significantly higher in the
multiple sclerosis group (36% v 8%). Patients
with multiple sclerosis with periodic leg
movements had higher MRI lesion loads in
infratentorial regions compared with patients
with multiple sclerosis without periodic leg
movements. However, spinal MRI was not
done and clinical findings were not reported
in detail. Thus, further studies are needed to
elucidate the prevalence and the pathogenesis
of restless legs syndrome and periodic leg
movements in patients with multiple
sclerosis.
In conclusion, our report suggests that
restless legs syndrome may occur secondary
to spinal cord lesions due to diVerent causa-
tive diseases including multiple sclerosis, spi-
nal cord injury, and cervical spondylotic
myelopathy. Similar to idiopathic restless legs
syndrome and other secondary forms, restless
legs syndrome due to myelopathy may
respond well to dopaminergic drugs.
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Coma in thrombotic thrombocytopenic
purpura
Patients with thrombotic thrombocytopenic
purpura (TTP) can present with devastating
neurological abnormalities.1 Mortality may
be as high as 95%, but current treatment has
reduced this to about 10% and early
treatment improves the rate of recovery.2 We
describe two patients who presented with
predominantly neurological symptoms and
signs who, because of a delay in making a
diagnosis of TTP, were referred for treatment
at a late stage. Both patients were reviewed by
neurological and haematological experts,
who considered that the prognosis was poor.
The first case was a 49 year old woman
with a longstanding diagnosis of schizo-
phrenia and a previous left sided cerebro-
vascular accident. She was admitted to her
local hospital with a 3 day history of
drowsiness, confusion, epistaxes, and sponta-
neous bruising, having been noted to be
increasingly agitated and disoriented over the
preceding 6 weeks. Her only medication was
trifluperazine and paroxetine. The second
case was a 58 year old man, previously fit and
well, who presented to his local hospital with
a 3 week history of confusion, drowsiness,
jaundice, and right upper quadrant pain. He
was taking no medication. The initial findings
in both patients are summarised in the table.
In both a diagnosis of TTP was made,
although this was not until 5 days after
admission in the first case, and both patients
were transferred to the intensive care unit for
plasma exchange and further management.
Treatment was started in both cases with
five cycles of plasma exchange, each cycle
using 3l cryodepleted fresh frozen plasma,
and in the first patient this was followed by a
course of oral prednisolone and azathioprine.
Both made an excellent recovery, with an
improvement in conscious level, a rise in
platelet count, disappearance of red cell frag-
ments, a fall in LDH and bilirubin concentra-
tions, and normalisation of renal function.
The first patient was self ventilating with no
neurological deficit at time of transfer back to
the referring hospital. The second patient had
a Glasgow coma score of 15 by the fifth day
of treatment, the only focal neurology being
a bilateral internuclear ophthalmoplegia
(INO)). Three months later the ophthalmo-
plegia had resolved and the patient was self
caring with minimal disability. Both patients
were extensively investigated to look for an
underlying cause for TTP, but none was
found.
Thrombotic thrombocytopenic purpura is
a syndrome comprising a pentad of
features—fever, thrombocytopenia, microan-
giopathic haemolytic anaemia, neurological
abnormalities, and renal dysfunction. Not all
five features are required to make the
Summary of patients
Patient 1 Patient 2
Age (y) 49 58
Sex F M
Platelet count (x109/l) 19 17
Peripheral blood film RBC fragments +++ RBC fragments +++
Clotting screen+fibrinogen Normal Normal
Bilirubin (µmol/l) 67 49
Lactate dehydrogenase (U/l) 1773 931
Creatinine (µmol/l) 121 131
Glasgoow coma score 3/15 3/15
Neurological findings Pupils equal and reactive, corneal
reflexes intact bilaterally; jaw jerk
brisk, gag absent; no motor
response to painful stimuli;
reflexes absent; upgoing plantars
Midposition, non-reactive pupils,
disconjugate gaze in all directions;
extension of all four limbs to painful
stimuli; plantars equivocal
Brain CT Normal Raised ICP, nil else.
Brain MRI Multiple foci of high intensity on
the T2 weighted images in white
matter of both cerebral
hemispheres and poles of lateral
ventricles
Normal, although only a scanning
MRI was done. A full MRI would
have been required to exclude a
midbrain lesion, but was not
technically possible.
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diagnosis—often fewer are present—and
there is no pathognomonic test, so diagnosis
may be diYcult. It is often considered along
with haemolytic uraemic syndrome (HUS)
to form part of a range of diseases called the
thrombotic microangiopathies. In these dis-
orders, intravascular platelet aggregation
(there is minimal fibrin deposition) leads to
obstruction of arterioles and capillaries,
causing local ischaemia. Thus TTP is seen
when the cerebral microcirculation is af-
fected, and HUS when the renal microcircu-
lation is aVected. An episode of TTP may
present as a one oV illness, may be
recurring,1 or may arise in association with
drugs, neoplasia, pregnancy, or HIV infec-
tion.
Thrombotic thrombocytopenic purpura
presents with neurological manifestations in
over 50% of episodes, with headache, confu-
sion, and somnolence being most common,
leading to focal neurological deficit, convul-
sions, and eventually coma and death.3 These
clinical features are often fleeting and fluctu-
ating and several important points regarding
imaging should be made. Firstly, brain CT
may be normal or may show multiple
hypodense areas indicative of generalised
cerebral oedema.4 Secondly, brain MRI may
also be normal, although it is likely to show
multiple foci of high intensity on T2 weighted
images.5 6 Coma has been shown to be a bad
prognostic indicator. Of importance is the
finding that despite the presence of substan-
tial neurological dysfunction, normal findings
on brain CT strongly suggest the potential for
full clinical recovery.6 7
Plasmapheresis is now the treatment of
choice: plasma infusion alone should not be
regarded as an acceptable alternative but as a
short term measure only.2 Fresh frozen
plasma is the usual replacement fluid, al-
though it remains to be determined whether
cryosupernatant or solvent/detergent fresh
frozen plasma is more eVective. These
plasmas lack von Willebrand factor, and since
ultralarge von Willebrand factor multimers
have been demonstrated in TTP, it is
postulated that additional factor exacerbates
the disease. Platelet transfusions should be
avoided (unless there is life threatening
bleeding) as they may worsen the condition.
These two cases illustrate that patients with
TTP may present to the intensive care unit
with profound coma, such that many clini-
cians would consider the prognosis so poor
that further active management would be
inappropriate. In addition, the cases show
that patients can survive and even make a full
recovery despite a delay in diagnosis and
appropriate treatment.
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Anaphylactoid reaction to methyl
prednisolone developing after starting
treatment with interferon â-1b
Courses of intravenous methyl prednisolone
are a routine treatment used for disabling
relapses in relapsing-remitting multiple scle-
rosis. The Interferon â-1b Multiple Sclerosis
Study Group’s research published in 1993
showed that interferon â-1b reduces the
frequency of relapses in this form of multiple
sclerosis.1 We present the case of a 35 year old
man with multiple sclerosis who became
allergic to intravenous methyl prednisolone
after the initiation of treatment with inter-
feron â-1b and discuss what part the drug
could have played in this.
A 35 year old man with asthma presented
early in 1994 with “dizziness”, double vision,
and paraesthesia in the right leg extending
into the trunk. He was found to have bilateral
pyramidal signs in the legs with extensor
plantar responses and gait ataxia. His CSF
contained oligoclonal bands. Visual evoked
potentials were normal. Brain MRI showed
multiple periventricular high density lesions
with a similar lesion identified on imaging of
the cervical cord, all consistent with demyeli-
nation. A 3 day course of intravenous methyl
prednisolone in May 1994 was associated
with improvement in his initial symptoms.
Four months later he presented with a VIth
nerve palsy which again responded to a 3 day
course of intravenous methyl prednisolone.
Between September 1995 and February 1996
he had a further four uneventful 3 day
courses of intravenous methyl prednisolone
for various symptoms related to his multiple
sclerosis. In March 1996 he was started on
interferon â-1b (8 MIU subcutaneously on
alternate days).
In June 1996 he was admitted with
pyramidal weakness of the left limbs, altered
sensation in the left leg and urgency of
micturition. Soon after starting his first dose
of intravenous methyl prednisolone he felt a
“lump” in his throat, developed an urticarial
rash on his limbs and trunk and began
wheezing audibly. Inhaled bricanyl was inef-
fective. Treatment was stopped and his peak
expiratory flow rate (PEFR) measured as 485
l/min. Chlorpheniramine (10 mg) was given
intravenously and after 5 minutes his PEFR
had returned to the lower limit of his normal
PEFR at 550 l/min. Further methyl pred-
nisolone was not given on this occasion.
In August 1996 he was admitted with
symptoms similar to those at his admission in
June 1996. Ten minutes after starting his first
dose of intravenous methyl prednisolone his
chest felt tight and he started developing a
similar urticarial rash. Again treatment was
stopped. Fifteen minutes later the rash had
worsened and he felt swelling in his mouth.
His symptoms settled after 10 mg intra-
venous chlorpheniramine. Further methyl
prednisolone was not given. After this episode
he chose to stop interferon â-1b.
In September 1996 he developed wheeze
and a rash after the first dose in a course of
intravenous methyl prednisolone. Subse-
quent doses in that course were preceded by
chlorpheniramine. In November 1996 he
developed nasal congestion and a rash after
500 mg methyl prednisolone. Again subse-
quent doses were preceded by a dose of chlor-
pheniramine. Since then he has been given
chlorpheniramine before each dose of intra-
venous methyl prednisolone, which he has
tolerated well.
Allergic reaction to steroids is rare and
anaphylactoid reaction to methyl pred-
nisolone is rarer still with only three reports
in the literature.2−5 One of these reactions
occurred in the course of treatment for mul-
tiple sclerosis. The allergic reactions are
more likely to be to the carrier than to the
steroid itself. Pathology in multiple sclerosis
is thought to be due to a delayed type hyper-
sensitivity reaction. The mechanism of
action of interferon â-1b in multiple sclerosis
is unknown, although several mechanisms
are postulated. There is evidence that,
among its many eVects on the immune
system, interferon â can increase
interleukin-2; and that interleukin-2 can
stimulate a Th2 response (found in allergic
type responses). These eVects would explain
the sequence of events in this man. However,
evidence suggests that interferon â is more
likely to suppress both Th1 (found in
delayed type hypersensitivity reactions) and
Th2 responses.6 It remains uncertain
whether the sequence of events here is due to
an eVect of interferon â-1b or to coinci-
dence. However, clinicians should be aware
that the complexity of the eVects of inter-
feron â-1b on the immune system may lead
to unexpected clinical outcomes.
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Poststreptococcal neuropathy
Streptococcal infection can lead to a wide
range of sequelae. Peripheral nervous system
injury is not well known as one of its possible
complications. We report a case with a typical
history for a poststreptococcal vasculitis
causing an axonal neuropathy of the right
common peroneal nerve.
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A 17 year old girl was referred by her gen-
eral practitioner due to the sudden onset of
numbness on the dorsum of her right foot
associated with stamping her foot on walking.
She had been well until 6 weeks previously
when she developed tonsillitis for which she
received a 1 week course of oral penicillin V.
She was also taking minocycline for mild
acne. As her throat recovered she developed
symmetric distal polyarthralgias and night
sweats which persisted as the numbness
developed. There was no history of trauma or
compression of the common peroneal nerve
at the neck of the fibula.
On examination she had a right foot drop
with weakness of ankle dorsiflexion (Medical
Research Council grade 3/5). There was
sensory loss in the distribution of the
common peroneal nerve. She was otherwise
neurologically intact with normal reflexes.
There were no skin lesions and her joints
were quiescent.
She had an erythrocyte sedimentation
rate of 87mm/h, a C reactive protein
concentration of 112 mg/l and an
antistreptolysin-O titre (ASOT) of 1600
units/ml. Autoimmune screen, antineuronal
antibodies, and cryoglobulins were all nega-
tive apart from an atypical perinuclear
antineutrophil cytoplasmic autoantibody (p-
ANCA) IgG titre of 160. Renal function was
normal and there were no casts on urine
microscopy.
Nerve conduction studies showed uniform
reduction of compound motor action poten-
tial amplitude from all sites of stimulation of
the right peroneal nerve with mild slowing of
conduction velocity. Sensory studies dis-
closed an absent response from the right
superficial peroneal nerve (table). F Wave late
responses were normal in the right tibial
(with true H response) and left peroneal
nerves, but delayed and inconstant in the
right peroneal nerve. Needle EMG was
normal in the right tibialis posterior muscle
providing evidence against the lesion being at
the L5 root level. There were, however, only
two units recruited from the right tibialis
anterior with small responses of long duration
and no spontaneous activity. The tests
confirmed a mainly axonal neuropathy of the
right common peroneal nerve with no
evidence of entrapment.
Because of its link with autoimmune
disease the minocycline was stopped al-
though it was not thought to have precipi-
tated her condition.1 She was treated initially
with oral prednisolone but developed a
vasculitic skin rash over the dorsum of both
feet. A biopsy showed deposits of C3 and
fibrin in the walls of some superficial dermal
vessels consistent with a vasculitis. A 3 day
course of intravenous methylprednisolone
was followed by azathioprine and pred-
nisolone. The decline in her ASOT and
inflammatory markers mirrored the improve-
ment in her systemic symptoms although on
stopping immunosuppression after a 2 month
course she developed erythema nodosum
necessitating further steroid therapy. Her foot
drop has improved although she has persist-
ent sensory loss.
In conclusion this is a 17 year old girl
with a typical poststreptococcal syndrome
associated with constitutional symptoms,
arthralgias, microscopic polyangiitis, and
later erythema nodosum. As part of her
illness she developed a mononeuropathy
with no evidence to suggest a specific
antineuronal process and likely to be due to
a necrotising vasculitis. It is unlikely that the
streptococcal infection has unmasked a con-
nective tissue disorder due to the negative
autoimmune screen apart from the atypical
p-ANCA and her improvement as the ASOT
fell. Vasculitis after streptococcal infection
has been well described.2 There are also
reports of vasculitis causing neuropathies
often as part of a connective tissue disorder.3
Surprisingly, streptococcal infection is not a
well known antecedent of peripheral nervous
system disease, even Guillain-Barré syn-
drome. There is a report of a 22 year old man
who developed a flaccid tetraparesis, raised
creatine kinase, and immune complex-
mediated rapid progressive glomerulone-
phritis after a group A streptococcal infec-
tion. A sural nerve biopsy showed an
inflammatory axonal neuropathy.4 There are
also two cases of mononeuritis multiplex
reported after â-haemolytic streptococcal
infections.2 5 Biopsy of the sural nerve from
one of these patients revealed a necrotising
vasculitis. Poststreptococcal immune-
mediated vasculitis should therefore be more
widely recognised as one of the causes of a
vasculitic neuropathy.
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A sensory level on the trunk and
sparing the face from vertebral artery
dissection: how much more subtle can
we get?
We read with interest the short report on sen-
sory loss in lateral medullary infarction by
Vuadens and Bogousslavsky.1 Unusual sen-
sory variants include contralateral leg and
lower trunk with ipsilateral lower face hyp-
algesia; or contralateral upper trunk, arm,
and face hypalgesia; or contralateral hypalge-
sia with facial sparing; or hemibody sensory
loss.1–3 We recently encountered a patient
with sensory loss of the spinothalamic type
involving only the contralateral leg and lower
trunk from vertebral artery dissection. The
sensory level in our patient with facial sparing
diVers from those in the literature; it suggests
a thoracic hemicord lesion and is false local-
ising.
A 44 year old, right handed man with no
relevant history presented with sudden onset
of vertigo and left eye pain. There was no his-
tory of trauma or neck manipulation. How-
ever, the patient had had a dental abscess
involving the lower incisors requiring drain-
age 4 weeks previously. He has a 30 pack-year
history of smoking. Vertigo developed while
he was changing his car tyre. He noted that
the vertigo was worse when he sat down and
put his head between his knees. The vertigo
lasted 15 minutes and was associated with
profuse sweating in the upper half of his body.
There was no nausea or vomiting. This
recurred twice that day each time lasting 15
minutes.
Examination disclosed normal visual acu-
ity and fundoscopy. There was scleral
injection in the left eye. The left pupil was 4
mm compared with 5 mm on the right. Both
reacted briskly to light. There was counter-
clockwise rotatory nystagmus in the primary
position. The eye movements were normal.
Corneal reflex was intact, as was sensation to
the upper and lower face. The other cranial
nerves were normal. The gag reflex was
brisk. There was no cranial bruit. Tone,
power, and reflexes were normal. The
sensory examination was normal to all
modalities. There was no upper limb ataxia.
He tilted to the left on sitting and on stand-
ing he fell to the left. The next day he noted
loss of pinprick and appreciation of tempera-
ture on the right leg and trunk with a sensory
level at T9 with preservation of touch, vibra-
tion, and joint position sense in all limbs
(figure).
Brain MRI showed a small infarct in the
lateral medulla and left cerebellum in the
Table Nerve conduction study results confirming a mainly axonal neuropathy of the right common
peroneal nerve
Motor conductions
Nerve/site CMAP Amplitude Terminal latency Velocity
Right tibial:
Ankle 32.0 mV 4.6 ms 49.3 m/s
Behind knee 6.6 mV
Right peroneal:
Ankle 3.7 mV 5.3 ms 44.8 m/s
Neck of fibula 3.4 mV 114.0 m/s
Behind knee 3.2 mV
Left peroneal:
Ankle 6.5 mV 4.9 ms 51.9 m/s
Neck of fibula 6.7 mV 50.0 m/s
Behind knee 9.1 mV
Sensory conductions:
Nerve Amplitude Onset latency Velocity
Right sural 11.0 µV 3.1 ms 41.9m/s
Right sup peroneal Absent
Left sural 9.6 µV 3.3 ms 39.4 m/s
Left sup peroneal 3.0 µV 3.3 ms 36.4 m/s
CMAP = Compound muscle action potential.
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distribution of the lateral branches of the left
posterior inferior cerebellar artery.4 There
was a crescent sign involving the left vertebral
artery from the skull base to the basilar artery
suggesting vertebral artery dissection (fig-
ure).
Four types of lateral medullary infarct are
recognised: small midlateral infarct, inferola-
teral infarct, and a large inferodorsolateral
and dorsolateral infarct. The topography of
the lesion in our patient corresponds to infe-
rolateral medullary infarct.3 The patients
with inferolateral infarcts and midlateral
infarcts in the literature were not recognised
to have cerebellar infarct and magnetic reso-
nance angiography in those patients was nor-
mal by contrast with our patient.3 The partial
lesion of the lateral spinothalamic tract in our
patient involved only the far lateral fibres
containing sacral aVerents leading to sparing
of the arm and face. The spinal trigeminal
nucleus and tract, which contain aVerents for
the face ipsilateral to the lesion, reside dorso-
laterally and the crossed ventral trigemi-
nothalamic tract, which contains aVerents for
the contralateral face, resides medial to the
lateral spinothalamic tract. Lesion of the
spinocerebellar tract involving only the sacral
fibres explains the presence of severe gait
ataxia but no upper limb ataxia.3 The
counterclockwise rotatory nystagmus is likely
due to imbalance of projections from the
anterior and posterior semicircular canals
and the otolith receptor.5
A sensory level to the trunk may point to a
lateral brainstem lesion in the presence of
other features suggesting brainstem disease.
In our patient these signs were transient and
sensory loss predominated. This new pattern
of sensory loss should be recognised as symp-
tomatic of lateral medullary infarction in
addition to other sensory variants.1–3
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Sudden unexpected death: a rare event
in a large community based prospective
cohort with newly diagnosed epilepsy
and high remission rates
It is now accepted that mortality in epilepsy is
significantly increased, with standard mor-
tality ratios raised twofold or threefold. Early
deaths are usually attributable to the underly-
ing cause of epilepsy and mortality in chronic
cases is commonly due to the epilepsy itself.1
Of the deaths that are directly related to epi-
lepsy, the commonest category is sudden
unexpected death in epilepsy (SUDEP). This
is widely defined as a sudden unexpected,
non-traumatic and non-drowning death in a
person with epilepsy with or without evidence
of a seizure and excluding documented status
epilepticus in which postmortem examina-
tion does not disclose a cause of death. Less
common causes are status epilepticus, acci-
dents due to seizures, drowning, and aspira-
tion. The National General Practice Study of
Epilepsy (NGPSE) is a prospective, popula-
tion based, observational study of 792
patients with newly diagnosed epilepsy (564
definite cases and 228 probable cases)2
followed up for 8000 patient-years and has
provided valuable insights into the prognosis
and mortality of epilepsy. Fifty per cent of the
definite cases were between the ages of 15
and 59 years—encompassing the age band in
which the phenomenon of SUDEP is most
commonly found. The overall standardised
mortality ratio among patients with definite
epilepsy in this cohort was 3.0 (95%
confidence interval (95% CI) 2.5–3.7).1
The true incidence of SUDEP is not
precisely known. Studies have varied in their
methodology and study populations have
ranged from those in death certificates and
coroners’ registers (more community based)
to epilepsy surgery cohorts and institutional-
ised patients (patients with chronic
epilepsy).3 Figures derived from community
based prospective studies indicate numbers
of up to 1:1100.4 Patients with chronic
epilepsy seem to have a much higher
incidence of SUDEP and a tertiary clinic
based population with chronic epilepsy in the
United Kingdom had an estimated incidence
of 1:200 patients.5 This is in some contrast
with the two SUDEP deaths in 5000 patient
years reported by the MRC Anti-epileptic
Withdrawal Study Group for patients in
remission from epilepsy.6
We report the first sudden unexpected
death in epilepsy in the NGPSE. A 42 year
old man known to have poorly controlled
idiopathic generalised epilepsy treated with
phenytoin and sodium valproate, was found
dead in bed, having been well in the hours
and days preceding death. He was known to
misuse alcohol and was questionably compli-
ant with medication, both factors thought to
increase the risk of sudden death. A necropsy
did not disclose any relevant pathology—
consistent with the definition of SUDEP.
Mortality has been studied in detail in this
large cohort1 and it was only in the 13th year
of follow up (8000 patient-years) that the first
SUDEP was reported. This could falsely give
the impression that SUDEP is a rare
occurrence and it must be borne in mind that
in large community based cohorts such as the
NGPSE, most patients enter remission from
seizures and it is the patients who continue to
have epilepsy that are most at risk from sud-
den death. Indeed in this cohort, the number
of patients who still have active epilepsy,
using International League Against Epilepsy
(A) Drawing of sensory deficit; (B) MRI showing clot in the left vertebral artery and infarcts in the
lateral medulla and cerebellum (arrows), (C) arrowhead pointing at the occlusion of the left vertebral
artery.
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criteria for remission (no seizures for 5 years
or more with or without medication) and on
follow up are 111 from an original 792 who
had definite or probable epilepsy. On its own,
therefore, it does not provide a true indication
of the incidence of SUDEP but it is
nevertheless an interesting finding on the
prognosis of epilepsy in a large, community
based cohort.
Financial support and sources of funding for the
NGPSE were the National Hospital for Neurology
and Neurosurgery, Brain Research Trust, and the
National Society for Epilepsy.
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Opportunities for improving the quality
of care in malignant cerebral glioma
There is scope for improving the services
oVered to patients with malignant glioma.
Clinical audit has highlighted several
important issues including some variation in
the management of patients aged over 60,1
delays in beginning treatment, and problems
with communication between diVerent
departments involved in patient care.2 A
multidisciplinary Working Group, funded by
the NHS Executive, recently developed
evidence based guidelines for the manage-
ment of these patients by surgery, radio-
therapy, and chemotherapy. The group also
considered the views of patients and their
relatives about follow up and psychosocial
aspects of care.3
We have derived a package of audit
measures from these guidelines that allow
treatment centres to assess the care that
they provide.4 Proformas within the package
cover various topics—for example, technical
aspects of treatment, breaking the news of
the diagnosis, the support of patients and
relatives, and palliative care while in the
community. Information is drawn from case
records, feedback from patients, relatives and
general practitioners, and review of the
policy a centre has already developed.
We piloted the proforma by reviewing the
case records of 60 patients diagnosed at two
treatment centres in London between 1992
and 1994. The table shows some results using
one proforma which covers breaking the news
of the diagnosis. We found, for example, that
overall most case records (67%,40/60) did
not record what the patient and their relative
had initially been told about the prognosis.
However, there did seem to be a diVerence
between centres. At one, clinicians rarely
recorded what they had said to patients and
relatives whereas at the other this was
recorded in just over 50% of cases. Patients at
one centre were also more likely to be seen
subsequently by counselling or palliative care
services. Neither centre had the benefit of a
dedicated specialist nurse in neuro-oncology.
The lack of a record does not, of course,
mean that the diagnosis and prognosis were
not actually discussed in some depth with the
patient and relative. However, clearly it is
likely to be helpful for others involved in the
care of the patient to have sight of such a
record. It is also possibly relevant that an ear-
lier study found that only a quarter of a sam-
ple of 75 patients drawn from diVerent
centres seemed to be fully aware of the likely
prognosis for their disease as they began
treatment.4
The aim of the guidelines developed by the
Working Group has been to suggest methods
which will help decision making in general
terms rather than provide firm guidance on
how particular patients should be treated. For
example, an initial assessment of patient dis-
ability is recommended. Ten of the 60 case
records we audited included some assessment
of disability, but none formally recorded the
patient’s performance status, an important
prognostic factor, using either the WHO
clinical performance status or the Karnofsky
score.
The current review of cancer services after
the Calman-Hine report5 represents an
opportunity for the development of neuro-
oncology services in Great Britain. A few
centres have made progress towards the ideal
of neuro-oncology clinics with specialist
nurse support and well developed links with
rehabilitation and palliative care. The guide-
lines and audit measures developed by the
Working Group will need to be adapted for
local circumstances, but treatment centres
and purchasers may find them a useful tool in
assessing and developing their services.
ELIZABETH DAVIES
MAUREEN BANNON
Research Unit, Royal College of Physicians, 11 St
Andrew’s Place, Regents Park, London NW1 4LE, UK
Correspondence to: Dr Elizabeth Davies, Research
Unit, Royal College of Physicians, 11 St Andrew’s
Place, Regents Park, London NW1 4LE, UK.
1 Whittle IR, Denholm SW, Gregor A. Manage-
ment of patients aged over 60 years with
supratentorial glioma: lessons from an audit.
Surg Neurol 1991;2:106–11.
2 Grant R, Collie D, Gregor A, et al. Referral pat-
tern and management of patients with malig-
nant brain tumours in South East Scotland.
Health Bull 1996;54:212–22.
3 Davies E, Hopkins A. On behalf of a working
group. Good practice in the management
of adults with malignant cerebral glioma:
clinical guidelines. Br J Neurosurg 1997;11:
318–30.
4 Davies E, Hopkins A, eds. Improving care for
patients with malignant cerebral glioma. London:
RCP Publications, 1997.
5 Calman-Hine Report. Expert Advisory Group
on Cancer. A policy framework for commis-
sioning cancer services. London: Department
of Health, 1995.
CORRESPONDENCE
MRI in vertebral artery dissection
In a recent report, Auer et al described the
clinical and imaging findings in 19 cases of
extracranial vertebral artery dissection
retrospectively.1 We make the following com-
ments.
Firstly, the authors described the
“sensitivity” and “specificity” of digital
subtraction angiography (DSA), magnetic
resonance imaging/angiography (MRI/A),
and duplex sonography for diagnosing ex-
tracranial vertebral artery dissection.1 These
figures were based on the percentage of
probable and definite features among the 19
patients. Nevertheless, sensitivity of a test is
the number of cases with true positive results
divided by the total number of positive
results (including both true and false
positives), and specificity is the number of
cases with true negative results over the sum
of true and false negatives. The authors
misquoted the terms “sensitivity” and “spe-
cificity” in their report, as the diagnostic cri-
teria of the various tests have not been
applied to a control group to disclose the
false positive cases and true negative cases.
Secondly, the criteria for case inclusion were
not defined. Apparently, extracranial verte-
bral artery dissection was diagnosed by
either radiological features on MRI/A (which
may be “pathognomonic” or “suggestive”) in
the appropriate clinical context or confirma-
tory radiological features on DSA (which
may be “specific” or “indirect”). The
accuracy and usefulness of DSA, MRI/A,
and duplex sonography cannot be compared
directly, as no single “gold standard” diag-
nostic method was used and because results
of the present study simply reflected the
proportion of cases diagnosed by the au-
thors.
Dissection of neck arteries was thought to
be an uncommon cause of ischaemic stroke.
The true incidence of this condition remains
unknown as angiography is not performed in
every patient during the acute or subacute
phase. Younger patients are more likely to
undergo early angiography when there is a
history of recent neck trauma2 or pain, or
when no other causes of stroke are apparent.
This selection bias may underestimate the
Record of explanation given to patients and relatives after the diagnosis and referral for counselling or
palliative care services. Figures are numbers (percentages of patients)
Centre A n=30 (%) Centre B n=30 (%)
Diagnosis explained to patient 8 (27) 6 (20)
Prognosis explained to patient 17 (57) 3 (10)
Prognosis explained to relative 15 (50) 8 (27)
Referral to counselling or palliative care service 12 (40) 2 (7)
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incidence of stroke due to arterial dissection
in older patients and those without neck
trauma or pain.
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Auer and Felber reply:
Cheung et al state in their comment, that dis-
sections of the neck arteries are an underesti-
mated cause of stroke, because angiography is
not performed in every patient during the
acute and subacute phase. This bias is even
more important in the case of vertebral artery
dissection if the initial symptoms are non-
specific. Non-invasive diagnostic methods are
likely to be performed earlier in these patients
and this was our motivation to report on the
magnetic resonance angiography of vertebral
artery dissection.
The diagnosis of vertebral artery dissection
is often based on the consensus of clinical and
neuroradiological features. We agree with
Cheung et al that no single “gold standard”
test for a dissection exists. Imaging precedures
more often show indirect signs which have to
be interpreted in the appropriate clinical con-
text. Therefore, the “inclusion criterion” we
used for this retrospective analysis was the
clinical and neuroradiological consensus on
the diagnosis of vertebral artery dissection.1
The sensitivity of DSA, ultrasound, and MRI/
angiography was determined from the find-
ings of the aVected and the contralateral nor-
mal vertebral arteries, there were no false
positive results. The term specificity could
have been misleading, because it did not refer
to the overall specificity of a test but to the
frequency of findings that reached a level of
specificity suYcient to establish the diagnosis
of vertebral artery dissection.1
Further prospective studies on the sensitiv-
ity and specificity of magnetic resonance for
the diagnosis of vertebral artery dissections
are certainly necessary, but our retrospective
evaluation already showed that MRI and MR
angiography will have a major contribution in
future. As a non-invasive means, magnetic
resonance can be employed without risk in
patients with non-specific symptoms and may
provide specific findings that are not accessi-
ble with other methods. This will lead to a
better estimation of the true incidence of dis-
sections and will improve the early diagnosis
and management of dissections in individual
patients.
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Clinical usefulness of MRI in
multisystem atrophy
Schrag et al suggest that certain putaminal
and infratentorial changes on MRI are useful
in distinguishing between patients with
multisystem atrophy (MSA) and patients
with idiopathic Parkinson’s disease.1 The
specificity and positive predictive value
of these changes were both about 90%.
However, whether these changes will
be useful in clinical practice or epidemio-
logical research is unclear for several
reasons.
The number of patients included was small
and so the confidence intervals were wide.
For example, the specificity of the MRI
changes for MSA could be as low as 80%.
Moreover, only patients with clinically prob-
able MSA were included. In this group of
patients the clinical diagnosis alone had a
positive predictive value as high as that of
MRI and so there would seem to be little
added value of MRI (14/15 (93%) patients
with probable MSA had the diagnosis
confirmed on postmortem). A more relevant
question is whether the MRI changes are
equally specific in those with possible MSA in
whom the clinical diagnosis is much less cer-
tain. Indeed it is also unclear from this study
whether the MRI changes are specific to
MSA as patients with other conditions that
enter into the diVerential diagnosis were not
included. It may therefore be more correct to
state that the MRI changes are helpful in
excluding Parkinson’s disease rather than in
confirming MSA.
Finally, the positive predictive value of
MRI quoted in this study is likely to be an
overestimate compared with its routine use
in most movement disorder clinics. Schrag et
al included a very high proportion of patients
with MSA (nearly 50%) compared with Par-
kinson’s disease. As the positive predictive
value is directly related to the prevalence of
the disease in a given population,2 this
resulted in a high positive predictive value. In
a typical movement disorder clinic, fewer
than 10% of patients will have MSA, in
which case, even if the specificity of MRI is
90%, the positive predictive value would only
be about 50%—that is, only half of those
with the MRI changes would turn out to
have the disease.
It is, therefore, too early to include specific
MRI changes as part of the diagnostic criteria
for MSA.
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Schrag and Quinn reply:
Counsell and Hughes raise several potential
drawbacks to our study1 that we willingly
acknowledge. Firstly, that the number of
patients included was small (about 45 in each
group); secondly, that the 1:1 proportion of
patients with Parkinson’s disease and those
with multiple system atrophy (MSA) atrophy
is unrepresentative of the real life situation in
which the ratio is >10:1. A more ideal study
might include 100 patients with MSA (to
help counter the criticism of small numbers)
and more than 1000 patients with Parkin-
son’s disease, but would be impractical,
particularly for the Parkinson’s disease group
who, unlike patients with atypical disease, are
not usually subjected to MRI. We agree that,
as clearly stated in the abstract, our study was
restricted to a comparison between multisys-
tem atrophy, Parkinson’s disease, and con-
trols, and are currently conducting a further
study additionally including patients with
other degenerative syndromes. Since the
completion of the report, patients with
Machado-Joseph disease have been reported
with similar infratentorial abnormalities.2 We
also agree that in the diagnosis of clinically
probable MSA, there is little added value of
MRI; involvement of the cerebellum and its
pathways is usually already clinically evident
before its demonstration by MRI or CT,3 and
even in cases without cerebellar involvement
the diagnosis is still a clinical one. Moreover,
as we emphasised, a minority of patients with
probable multisystem atrophy have a normal
MRI. Therefore, unlike others,4 we have
never proposed MRI changes as part of the
diagnostic criteria for multisystem atrophy.
As discussed, the sensitivity of the method
may be lower early, and higher late in the dis-
ease. However, for the purpose of validation
of a proposed diagnostic aid imaging findings
need to be related to a clinically probable
diagnosis rather than a possible diagnosis.
The “gold standard” is definite, pathologi-
cally confirmed disease, but this was achieved
in only one patient in our series. In
conclusion, we nevertheless think that our,
admittedly imperfect, blinded MRI study
(the first conducted in MSA) has helped to
determine the prevalence of certain MRI
abnormalities in patients with clinically prob-
able MSA in comparison to patients with
Parkinson’s disease and controls . It has also,
perhaps more importantly, revealed the limi-
tations of MRI in this context. However,
expert clinical evaluation remains the corner-
stone of the diagnosis in life, and it is also
more cost eVective than resorting to expen-
sive imaging techniques.
A SCHRAG
N P QUINN
Department of Clinical Neurology, Institute of
Neurology,
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A dubious therapy for patients with
multiple sclerosis
Plohmann et al1 investigated the eVects of
computer training of attentional deficits in
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patients with multiple sclerosis. They con-
clude that “significant improvements of
performance could almost exclusively be
achieved by the specific training pro-
grammes”. The validity of this conclusion is
called into question by severe methodical
shortcomings of their study.
Before training, three baseline measure-
ments of attentional functions were adminis-
tered with 3 week intervals. For evaluation of
training eVects the median value of the three
baseline measurements was compared with
the values obtained after training. This statis-
tical approach manifests a curious misunder-
standing of the purpose of repeated baseline
measurements. They serve to determine a
baseline, that is, a rate of change occurring
without any therapy. The critical value is
therefore not the mean (or median) of the
baseline measures but the diVerence between
them. If therapy is eYcient, the diVerence
between pretherapy and post-therapy
measurement should be greater than that
between two consecutive baseline measure-
ments. This crucial comparison is not
presented.
The selection of the median of the three
baseline measurements as starting point for
calculation of improvements during the first
training period poses further problems. If
there was any improvement from the first to
the third baseline measurement, the median
is lower than the third measurement after
which training began. This diVerence inflates
apparent improvement in the first training
period. It may feign specific training eVects if
the training group had a steeper baseline
than the control group. A possible reason for
diVerent baselines are diVerent severities of
initial impairment. We (Motz, Grömminger,
Göttert, Goldenberg, unpublished data)
have administered the PASAT,2 another test
of attentional capacities, four times with
weekly intervals to 30 patients with chronic
brain damage from diVerent aetiologies.
During intervals these patients did not
receive any training of attentional functions.
Thus, the repeated measurements deter-
mined a baseline without therapy. None the
less, perfomance on PASAT improved from
test to test. There was a negative correlation
between intitial performance and improve-
ment. Patients with poor initial performance
improved more than those with better
performance.
The allocation of patients to treatment
groups in the study of Plohmann et al was not
randomised. Patients were trained in those
two functions that were aVected most, and
group comparisons were made between
patients who had been trained in a function
and those who were not. Thus the training
group tended to start from a lower level of
performance than the control group. Figures
2 and 3 of their paper illustrate this eVect
impressively. If, as suggested by our results
with the PASAT, initial level of impairment
has a systematic influence on improvement
independently of any therapy, the allegedly
specific training eVect may be accounted for
by the diVerences in initial level.
Whether or not the results of Plohmann’s et
al study are reliable has clinical and ethical
implications. Multiple sclerosis is one of the
most common neurological diseases, and I
have the suspicion that no other neurological
disease has given rise to a comparable
number of scientifically unfounded therapies
and advice. The above critique raises the
possiblity that computer assissted retraining
of attention is one of them. It may be
relatively harmless in that it has no organic
side eVects. None the less, if its eYcacy can-
not be proved, it would be a waste of money,
time, and patients’ hopes.
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Plohmann and Kappos reply:
We thank Goldenberg for his interest in our
paper1. After having been actively involved in
planning and conducting controlled trials in
multiple sclerosis in the past 15 years, we can
only agree that the risk of drawing wrong
conclusions from unreliable data cannot be
overstressed in this area. All the same we can-
not follow Goldenberg’s reasoning. His cri-
tique is probably based on his own unpub-
lished observations but is neither supported
by the available literature nor by our own
data.
His main critique is that the eVect
described in our paper may only reflect non-
specific practice eVects. Retest eVects are
dependent on the interval between test pres-
entations and the population studied, and
diVer from test to test according to their
respective stability and reliability. In our
study we assessed patients with multiple scle-
rosis in a stable or eventually slightly progres-
sive phase of their disease. For cognitively
impaired patients with multiple sclerosis it
has been shown in longitudinal studies that
they lack practice eVects compared to cogni-
tively intact patients.2 3 In our data a possible
but in no way significant practice eVect was
found between the first (T1) and second (T2)
baseline (pretreatment) measurement and—
with two exceptions (“divided attention” and
“flexibility”)—not at all between T2 and T3.
Clearly significant improvement of perform-
ance could only be seen between all three
baseline measurements and T4 (Friedman
two way analysis of variance, Wilcoxon signed
ranks test). Also the assumption that the
median might be lower than the third
measurement and therefore might not be an
adequate starting point for statistical com-
parisons is not supported by our data. In
most of the control tests the median is equiv-
alent to T3 or even larger.
Goldenberg’s second point is that the
initial level of performance has a systematic
influence on improvement independently of
any therapy. Furthermore, on the basis of his
results concerning the PASAT, he assumes a
negative correlation between initial perform-
ance and improvement. As our patients had
received specific training in those two func-
tions that were severely impaired and thus
started from a lower level of performance,
Goldenberg claims that the specific training
eVects may be accounted for by the diVer-
ences in initial level of impairment. For this
reason we reanalysed our data. For each
training group we built subgroups of patients
according to their initial capability (low,
medium, high) and printed the course of per-
formance during the baseline measurement
(T1-T3). Our results do not confirm Golden-
berg’s assumption that initial level of per-
formance has a systematic or inverse influ-
ence on improvement.
Nevertheless, as already stated in our origi-
nal paper, due to the small sample size of our
study the results do not allow a definite
assessment of the training and its eVects in
patients with multiple sclerosis; but they pro-
vide enough evidence to encourage further
studies in a larger population of patients.
Thus, we have started a prospective multicen-
tre study in comparison with three Swiss
neurological rehabilitation centres to further
assess and possibly improve this kind compu-
ter assisted retraining of attentional func-
tions.
The unpublished additional data mentioned in our
letter have been submitted with this letter and are
available on request (tables 1a-1c, figures 1 and 2).
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Neurology and the gastrointestinal
system
Neurology and the gastrointestinal system,1
or an analysis of the “brain/gut” axis would
be incomplete without allusion to the
neuroendocrine system, and its mediation,
via somatostatin, in the regulation of
splanchnic blood flow and gastric acid
secretion.2 3 These actions could account for
the established haemostatic action of soma-
tostatin in oesophageal variceal bleeding,4
and for the perception, derived from meta-
analysis, that similar benefits might occur in
non-variceal upper gastrointestinal
haemorrhage.5 On the basis of the involve-
ment of somatostatin in the regulation of
gastric blood flow and acid secretion, it also
seems reasonable to attribute gastric erosive
bleeding, so-called Cushing’s ulcers, which
occur in CNS disorders,6 to derangements in
neuroendocrine pathways.
OMP JOLOBE
Department of Medicine for the Elderly, Tameside
General Hospital, Fountain Street, Ashton-under-Lyne
OL6 9RW, UK
1 Perkin GD, Murray-Lyon I. Neurology and the
gastrointestinal system. J Neurol Neurosurg Psy-
chiatry 1998;65:291–300.
2 Bosch J, Kravetz D, Rodes J. EVect of somato-
statin on hepatic and systemic hemodynamics
in patients with cirrhosis of the liver: compari-
son with vasopressin. Gastroenterology 1981;80:
518–25.
3 Bloom SR, Mortimer CH, Thorner MO, et al.
Inhibition of gastrin and gastric acid secretion
by growth hormone release-inhibiting hor-
mone. Lancet 1974;ii:1106–9.
4 Saari A, Klvilaasko E, Inberg M, et al. Compari-
son of somatostatin and vasopression in bleed-
ing esophageal varices. Am J Gastroenterol
1990;85:804–7.
Letters, Correspondence, Book reviews 695
 on 2 November 2006 jnnp.bmjjournals.comDownloaded from 
5 Imperiale TF, Birgisson S. Somatostatin or
octreotide compared with H2 antagonists and
placebo in the management of acute non-
variceal upper gastrointestinal hemorrhage: a
meta-analysis. Ann Intern Med 1997;127:1062–
71.
6 Isselbacher KJ, KoV RS. Hematemesis and
melena. In: Thorn GW, Adams RD, Braunwald
E, et al, ed. Harrison’s principles of internal medi-
cine. 8th eds. Tokyo: McGraw Gill, Kogakusha,
1977:214–18.
BOOK REVIEWS
Greenfield’s Neuropathology. Sixth
Edition. Volume 1 and 2. Edited by DAVID I
GRAHAM and PETER L LANTOS. (Vol 1 pp 1230,
Vol 2 pp 989). Published by Arnold,
London, 1997. ISBN 0-340-59809-3
“All we really understand about neurological
disease we have learned from pathological
studies.”
Self evidently not a perfect truth, but it is a
fair approximation, particularly if “under-
stand” is properly weighted. Take multiple
sclerosis as a random example. We have been
taught a great deal about the course and
dynamics of the disease—for example, by
new imaging techniques, but MRI has come
closest to contributing to our understanding
of the disorder when married to pathological
studies, or when used as a surrogate marker
of pathology. The huge power of the new
genetics has now set its sights on multiple
sclerosis, and although proceeding apace and
well in to the genome screen approach, it too
has yet to contribute major insights to our
understanding of multiple sclerosis. Animal
models, even the aged EAE, can only oVer
suggestions which live or die according to
correlative studies of multiple sclerosis tissue
or patients. And my own area of interest, the
cell biology of oligodendrocytes studied
(mostly) by cell culture, is no better or worse
than these other tools: it can make sugges-
tions which must be tested by direct examina-
tion of tissue—by pathology.
It follows that good neurology must
depend on a decent grounding in pathology,
and a neurological training which fails to
include and indeed emphasise pathology is a
poor and incomplete one. Calman’s prescrip-
tion for postgraduate education presents an
opportunity formally to ensure that training
schemes do not permit the possibility of such
deficiency. So would the sixth edition of
Greenfield’s Neuropathology feature on an ide-
alised neurological curricular reading list? It
could not fail to.
To continue with the above example, the
account of demyelinating disease—and with
what better subject to start? Considering
Greenfield’s own contributions to the pathol-
ogy of multiple sclerosis, the most conspicu-
ous at present is his definitive study of axon
loss in multiple sclerosis, which surely is one
of the finest wheels to be reinvented. This
must be as good an account as any available.
It is (not withstanding the book’s two
volumes and 2200+ pages) not overly
long—86 pages, but strikingly well struc-
tured, generously (and often beautifully)
illustrated with 95 figures, the great majority
photomicrographs and many in colour, and
closely and carefully argued, with over 500
references. Prineas and McDonald have
combined and distilled their unique and
enormous experience to provide a scholarly,
authoritative, and yet wholly readable review
of multiple sclerosis and the associated
demyelinating diseases, a benchmark account
against which current and future eVorts must
be measured.
How to move on, to provide anything
remotely resembling a useful review of the
remaining 25 chapters? Several merit particu-
lar attention. “Prion diseases” (DeArmond
and Prusiner) and “tumours of the nervous
system” (Lantos, Vanden Berg, and Kleihard)
are both new to Greenfield’s book. Both rep-
resent topics whose biology and pathology
have changed at a breathtaking pace over the
past five years, a sure challenge to any
textbook harbouring ambitions of definity.
Typically, both rise to the call with apparent
ease. The chapter on prion disease is only 35
pages long, but this is nevertheless a compre-
hensive and fine account of an extraordinary
area of the human neurology and neuropa-
thology. There are excellent descriptions not
only of conventional dementing prionopa-
thies, but also of rarer, more recently
recognised entities such as fatal familial
insomnia. The biological controversies and
molecular dissection of the disease are amply
covered, and space is even found for specula-
tion concerning the possible involvement of
prions, in yet another evasive and tantalising
disease, inclusion body myositis.
The tumour chapter—an all embracing
200 pages with more than 3000 references (I
lost count)—is again quite masterly. The
bread and butter tumours are capably
described, and there are instructive and use-
ful accounts of other important areas—
familial tumours, metastatic disease, etc.
Again, the narrative is as contemporary as a
large text can be, and more up to date than
most, with succinct descriptions of the NF
siblings neurofibromin and merlin, and of
their biology, as far as is known. Surprisingly,
in this generous chapter, paraneoplasia is
perhaps a little brief.
It would be unforgivable also to omit men-
tion of the chapter on peripheral neuropathy
(Thomas, Landon, and King). Just 100 pages
long, this yet again is a joy to read. The first
fifth is devoted exclusively to a description of
the normal peripheral nerve, an outstanding
account. The whole chapter is (predictably)
beautifully illustrated, with authority spread
deep and thick and even across the whole
landscape of peripheral nerve disease, from
new immunological concepts in relation to
inflammatory neuropathies, to the molecular
genetic advances in inherited nerve disease.
So, it is not easy to criticise. I managed to
amass a perfectly miserable haul of just one
typo (though quite a howler—BAL for
BALO—in a bold, italicised, large font
header). The editing is lightly but highly
eVectively administered, and there are very
few outright omissions. I could find no
account of Hashimoto’s encephalopathy,
which is a shame; I suspect many years of
further use might fail to add appreciably to
this one omission.
This is such a good book. Do buy one. It is
well worth the investment, and will stand by
you and repay you all the days of your work-
ing life.
NEIL J SCOLDING
Management of Stroke: A Practical
Guide for the Prevention, Evaluation
and Treatment of Acute Stroke. Edited
by HAROLD P ADAMS, GREGORY J DEL ZOPPO,
and RUDIGER VON KUMMER. (pp224, $17.95).
Published by Professional Communications,
New York, 1998. ISBN 1-884735-35-5.
I was very keen to read this book—mainly
because I have heard one of the authors state
publicly that stroke patients are being trans-
ported by air ambulance to emergency
rooms in parts of California and I was won-
dering whether he would advocate this in
print. Sadly the nearest he got was “The
message to the public is simple: the goal is to
take the patient to the emergency room as
fast as possible using emergency medical
transportation and transfer the patient to a
hospital that has brain imaging tests available
on a 24 hour a day 7 day a week basis.” Not
quite, but the tenor of the book is described
—controversial, not overtly dangerous but
rather premature, and, for most parts of the
United Kingdom, a work of fiction (at least
for the moment).
It is one of those slimline varieties meant
for the white coat pocket and is obviously
aimed at the emergency room doctor eagerly
awaiting an acute stroke patient to be flown
in, scanner and thrombolytic infusion ready
to go. The relevant chapter is right in the
middle of the book and for anyone involved in
the day to day care of stroke patients it is fan-
tastic, just like the famous “brain attack!’ epi-
sode of the television series “ER”. There are
tables describing how to monitor patients,
how to administer TPA and how to set up
labetalol or sodium nitroprusside infusions
for hypertension poststroke. Sandwiched
between are rather more ordinary notes on
prevention, stroke units (one page), transient
ischaemic attacks, and diagnosis of the stroke
syndromes plus the basic management of
subarachnoid haemorrhage and intracranial
haemorrhage (with a rather worrying table on
the acute management of haemorrhage post-
thrombolysis !).
Perhaps the most practical chapter is on the
diagnosis and evaluation of patients with
stroke which is full of helpful tables but again
basically designed as a screening tool for
patients suitable for thrombolysis. The text is
full of “Americanisms” such as “bronchopul-
monary toilet” which I found very amusing
and kept me reading in places rather like a
Bill Bryson.
The worst chapter is on the imaging of the
brain and blood vessels and here the book
could have been much better. Most of the CT
brain images are overexposed and on black
and white paper. Although there are arrows
indicating to the reader where to look, most
of the scans are uninterpretable. Obviously
this is a key area in making treatment
decisions with thrombolytic drugs and I was
disappointed that this was not done better.
Unfortunately the last few chapters are
brief add-ons and could have been left out—a
rather impractical section on neuroprotection
and a miserly three pages covering rehabilita-
tion and discharge planning.
This book rides on the edge of the evidence
and is certainly the “Californian way”. The
authors are to be congratulated for their cam-
paigning zeal for the emergency management
of stroke which some of us hope will become
more widespread. However, it could be argued
that at the present time a more useful practical
stroke guide would cover how to set up a
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neurovascular clinic and stroke unit, how to
overcome resistance to change, how to partici-
pate in or set up large multicentre trials etc.
Whether you read this book will largely
depend on your point of view.
LIZ WARBURTON
Disorders of the Brain and Mind. Edited
by MARIA A RON and ANTHONY S DAVID. (Pp
375, £55.00). Published by Cambridge
University Press, Cambridge, 1998. ISBN
0-521-47306-3.
In choosing the title for this book, the editors
have wisely avoided the use of the term “neu-
ropsychiatry”, which in Britain, at least,
implies a primarily psychiatric audience. I
think that this book should be read by a much
wider audience, including neurologists inter-
ested in behaviour and cognition. There are
relatively few books available that bridge this
important divide. The editors have assembled
an impressive international cast who cover
most of the hot topics at the interface of neu-
rology and psychiatry.
The first section is dedicated to the frontal
lobes with contributions from neuropsychol-
ogy and frontal lobe abnormalities on struc-
tural scanning in schizophrenia. The second
section deals with basal ganglia disorders
with excellent overviews of neuropsychologi-
cal findings and behavioural psychopharma-
cology. The third section is dedicated to
memory and its disorders, with extremely
readable overviews of advances and contro-
versies in the neuropsychology of memory
and clinical disorders. The fourth section
deals with psychiatric manifestations of pa-
tients with a known brain pathology and
structural imaging in the psychoses. Stricter
editorial intervention could have avoided
some redundancy and overlap with an earlier
chapter. Section five covers for what is for
many people the central ground of
neuropsychiatry—namely, epilepsy—with ex-
cellent accounts of the behavioural and
psychiatric changes seen in the context of
chronic epilepsy. The sixth section takes a
developmental perspective, particularly re-
lated to schizophrenia, and the final two
chapters of the book deal with advances in
brain imaging, namely magnetic resonance
spectroscopy and imaging of patients with
hallucinations.
The editors have deliberately decided not
to write a comprehensive textbook, but rather
to choose areas of advance and controversy,
and in doing so have produced a very
readable text. The book is in many ways a
celebration of the immense contributions of
Professor Alwyn Lishman to the study of the
brain and mind. I can thoroughly recommend
it to everyone working in this exciting area.
JOHN HODGES
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